MacroGenics, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter filing. MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based cancer therapies. The FDA approved its first product, MARGENZA, in December 2020; a U.S. launch with EVERSANA was expected in March 2021. FY2020 revenue was primarily from collaborations and government agreements, not product sales.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Total revenue | $104.9 million | $64.2 million |
| Research and development expense | $193.2 million | $195.3 million |
| General and administrative expense | $42.7 million | $46.1 million |
| Loss from operations | $(131.1) million | $(177.2) million |
| Net loss | $(129.7) million | $(151.8) million |
| Basic and diluted loss per share | $(2.47) | $(3.16) |
| Net cash used in operating activities | $(111.9) million | $(134.3) million |
Revenue rose 63%, primarily due to $40.0 million in Incyte development milestones, a $20.0 million Janssen upfront payment, and a $12.0 million payment from Boehringer Ingelheim to retain rights. Operating expenses declined about 2%, while net loss narrowed about 15%. Other income fell to $1.3 million from $25.4 million, partly because 2019 included gains from Provention warrants and higher investment income. The company remained loss-making; FY2020 operating loss was greater than revenue.
At year-end, cash and cash equivalents were $181.1 million and marketable securities were $91.4 million, totaling $272.5 million, versus $215.8 million a year earlier. Current assets were $312.6 million and current liabilities $50.7 million. Total liabilities were $82.9 million, including $29.2 million of lease liabilities; the filing reports no borrowings or other conventional debt. Financing cash flow was $174.3 million, including $170.5 million net proceeds from common-stock sales. The share count rose to 56.2 million from 49.0 million.
Management estimated that year-end cash, cash equivalents and marketable securities, together with anticipated and potential collaboration payments and product revenue, would fund operations into 2023, assuming programs and collaborations progress as planned. The company had an accumulated deficit of $771.8 million and expected continuing losses. No product-sales revenue or royalty revenue had yet been recognized.
Business developments, outlook and risks
- MARGENZA: FDA-approved with chemotherapy for adults with metastatic HER2-positive breast cancer after at least two prior anti-HER2 regimens. In SOPHIA, median progression-free survival was 5.8 months versus 4.9 months for trastuzumab plus chemotherapy (hazard ratio 0.76; p=0.033). Final overall-survival results were expected in the second half of 2021; an earlier interim OS analysis was not statistically significant. The label includes a boxed warning for left ventricular dysfunction and embryo-fetal toxicity.
- Pipeline: The filing describes eight immuno-oncology clinical programs. Flotetuzumab’s registrational-path trial enrollment was slower than expected amid COVID-19. Other clinical programs include tebotelimab, enoblituzumab, MGC018 and MGD019; reported early clinical activity is preliminary and does not establish approval or commercial success.
- Partnerships and revenue concentration: Incyte generated 47% of FY2020 revenue; Janssen 19% and Zai Lab 11%. Janssen’s December 2020 agreement provided a $20.0 million upfront payment, research funding, potential milestones up to $312.0 million and royalties up to 10%. Collaboration milestones and payments are contingent and may vary by period.
- COVID-19: Management reported slowed clinical-trial enrollment and anticipated near-term effects on study initiation and enrollment. The company delayed an enoblituzumab study and stopped enrollment in an ex-U.S. flotetuzumab/retifanlimab study. Further effects on trials, manufacturing, commercialization and liquidity remained uncertain.
- Other risks and contingencies: Key risks include clinical and regulatory failure, competition (including newer HER2 therapies and biosimilars), reimbursement and market acceptance, manufacturing and supply dependence, future financing needs, intellectual-property challenges and reliance on collaborators. A securities class action relating to statements about the SOPHIA trial remained pending; the company had not accrued a loss because the outcome and any loss range could not be reasonably estimated.
Most important facts to verify
- Whether MARGENZA launched as planned and achieved meaningful uptake, reimbursement and sales after FY2020.
- The final SOPHIA overall-survival results and any resulting regulatory, labeling or commercial implications.
- Actual cash burn, collaboration receipts and financing needs relative to management’s “into 2023” runway estimate; note the estimate assumes planned program progress and potential payments.
- Progress, enrollment, safety and confirmatory evidence for key pipeline programs, particularly flotetuzumab and the MARGENZA-related studies.
- Updates to the pending securities litigation, manufacturing capacity and supply arrangements, and the company’s collaboration revenue concentration.
The financial statements received an unqualified audit opinion from Ernst & Young, and the auditor also concluded internal control over financial reporting was effective as of December 31, 2020.